Features of intestinal microbiota in ulcerative colitis
https://doi.org/10.31146/1682-8658-ecg-179-7-78-85
Abstract
The study is dedicated to one of the most discussed problems of the last decade, not only in gastroenterology, but also in the scientific world. The more knowledge and ideas we have about the composition and function of the microbiota of the human body, in particular the microflora of the gastrointestinal tract, as one of the most populated department by microorganisms of the human body, the better we realize that we are only at the beginning of the this way. The evolution of methods for diagnosing of microbiota from microbiological method to modern molecular genetic techniques to isolate the genetic material of bacteria, of course, plays a key role in our understanding of this issue, attempts to establish the role of microorganisms in the development of diseases of various human systems. Inflammatory bowel diseases, including ulcerative colitis, belong to pathological conditions with an unclear etiology characterized by a chronic severe course, a diverse clinical picture, difficulty in establishing a diagnosis, long-term treatment. In this research with the modern diagnostic methods an attempt is made to come closer to understanding the changes that occur in the intestinal microbiota with ulcerative colitis, identifying probable etiological and pathogenetic agents, and identifying possible targets for exposure as additional methods of treating the disease.
About the Authors
V. A. Kupaeva
Russian Medical Academy of Continuous Professional Education; State Scientific Centre of Coloproctology
Russian Federation
Russian Federation
Victoria A. Kupaeva - Assistant of the Department of Gastroenterology, Gastroenterologist of the clinic.
Moscow.
I. D. Loranskaya
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Irina D. Loranskaya - Doctor of Medical Science, Professor, Head of the Department of Gastroenterology.
Moscow.
M. N. Boldyreva
NRC Institute of Immunology FMBA of Russia
Russian Federation
Russian Federation
Margarita N. Boldyreva - Doctor of Medical Science, Senior research associate.
Moscow.
B. A. Nanaeva
State Scientific Centre of Coloproctology
Russian Federation
Russian Federation
Bella A. Nanaeva - PhD, Head of gastroenterological department.
Moscow.
M. V. Shapina
Russian Medical Academy of Continuous Professional Education; State Scientific Centre of Coloproctology
Russian Federation
Russian Federation
Marina V. Shapina - PhD, Chief of the inflammatory and functional bowel diseases unit, Associate Professor of the Department of Coloproctology.
Moscow.
References
1. Adler G. Bolezn' Krona i yazvennyj kolit. M.: GOETAR-MED, 2001. 500 P.
2. Klinicheskie rekomendacii rossijskoj gastroentero-logicheskoj associacii i associacii koloproktologov Rossii po diagnostike i lecheniyu yazvennogo kolita. Koloproktologiya. 2017. no. 1(59), pp.6-30.
3. Loranskaya I. D., Khalif I. L., Boldyreva M. N., Kupaeva V. A. Characteristic of microbiome in inflammatory bowel disease (Review) . Experimental and Clinical Gastroenterology. 2018;(5):104-111. (In Russ.)
4. Loranskaya I. D. et al. Pristenochnaya mikroflora kishechnika. M.: Prima Print, 2015. 100 P.
5. Rebrikov D. V. et al. PCR v real'nom vremeni. 7-e izd. M.: Laboratoriya znanij, 2019. 223 P.
6. Chaplin A. V., Rebrikov D. V., Boldyreva M. N. Mikrobiom cheloveka. Vestnik RGMU. 2017, no. 2, pp. 5-13.
7. Andrews C.N., Griffi ths T. A., Kaufman J. et al. Mesalazine (5-aminosalicylic acid) alters fecal bacterial profiles, but not mucosal proteolytic activity in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2011. no. 34(3), pp. 374-83.
8. Bharadwaj R. S. Role of bacteria in Inflammatory bowel disease (IBD). International Journal of Infectious Diseases. 2016, Vol.45, Suppl. 1, pp. 134.
9. Biasco G., Zannoni U., Paganelli G. M.et al. Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis. Cancer Epidemiol. Biomarkers Prev, 1997, no. 6, pp.469-471.
10. Frank D.N., Amand A. L. St, Feldman R. A. et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U.S.A, 2007, no. 104, pp.13780-13785.
11. Frick J.S., Autenrieth I. B. The gut microflora and its variety of roles in health and disease. Curr Top Microbiol Immunol, 2013, no. 358, pp.273-89.
12. Huang E.Y., Inoue T., Leone V. A. et al. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm Bowel Dis, 2015, no. 21(5), pp. 963-72.
13. Kabeerdoss J., Sankaran V., Pugazhendhi S. et al. Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India. BMC Gastroenterol, 2013, 13:20.
14. Man S.M., Kaakoush N. O., Leach S. T. et al. Host attachment, invasion, and stimulation of proinflammatory cytokines by Campylobacter concisus and other non-Cam-pylobacter jejuni Campylobacter species. J. Infect. Dis, 2010, no. 202, pp.1855-65.
15. Nagao-Kitamoto H., Kamada N. Host-microbial Crosstalk in Inflammatory Bowel Disease. Immune Netw, 2017, № .17(1), pp.1-12.
16. Shin S.J., Collins M. T. Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. Antimicrob Agents Chemother, 2008, no. 52(2), 418-26.
17. Sokol H., Seksik P., Rigottier-Gois L. et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm. Bowel Dis, 2006, no. 12, pp.106-111.
18. Swidsinski A., Loening-Baucke V., Bengmark S. et al. Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. Inflamm Bowel Dis, 2007, no. 13(1), pp.51-6.
19. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, Vol. 11, Issue 6, pp. 649-670.
20. Vermeiren J., Van den Abbeele P., Laukens D. et al. Decreased colonization of fecal Clostridium coccoides/ Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. FEMS Microbiol Ecol, 2012, no. 79, pp. 685-96.
21. Wills E.S., Jonkers D. M., Savelkoul P. H. et al. Fecal microbial composition of ulcerative colitis and Crohn's disease patients in remission and subsequent exacerbation. PLoS One, 2014;9(3): e90981.
22. Wilson J.C., Furlano R. I., Jick S. S. et al. Inflammatory bowel disease and the risk of autoimmune diseases. J Crohns Colitis, 2016, no. 10, pp.186-93.
Review
For citations:
Kupaeva V.A., Loranskaya I.D., Boldyreva M.N., Nanaeva B.A., Shapina M.V. Features of intestinal microbiota in ulcerative colitis. Experimental and Clinical Gastroenterology. 2020;(7):78-85. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-179-7-78-85
Views:
435
Email this article 